136 related articles for article (PubMed ID: 15996092)
21. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
22. Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
Alsaeedi S; Keystone EC
Nat Rev Rheumatol; 2014 Oct; 10(10):578-9. PubMed ID: 25090946
[No Abstract] [Full Text] [Related]
23. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Frampton C; James J; Barclay ML
Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
[TBL] [Abstract][Full Text] [Related]
24. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis.
Hamilton RA; Kremer JM
Br J Rheumatol; 1997 Jan; 36(1):86-90. PubMed ID: 9117183
[TBL] [Abstract][Full Text] [Related]
25. [The initial results of the Metex Study].
Braun J
Krankenpfl J; 2005; 43(7-10):246-7. PubMed ID: 16515316
[No Abstract] [Full Text] [Related]
26. Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis.
Heuvelmans J; den Broeder N; van den Elsen GAH; den Broeder AA; van den Bemt BJF
Rheumatology (Oxford); 2021 Dec; 61(1):331-336. PubMed ID: 33788911
[TBL] [Abstract][Full Text] [Related]
27. Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?
Pincus T; Sokka T
Rheumatology (Oxford); 2006 May; 45(5):497-9. PubMed ID: 16537578
[No Abstract] [Full Text] [Related]
28. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
29. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
Lu LJ; Bao CD; Dai M; Teng JL; Fan W; Du F; Yang NP; Zhao YH; Chen ZW; Xu JH; He PG; Wu HX; Tao Y; Zhang MJ; Han XH; Li XF; Gu JR; Li JH; Yu H
Arthritis Rheum; 2009 Jul; 61(7):979-87. PubMed ID: 19565542
[TBL] [Abstract][Full Text] [Related]
30. An update on methotrexate.
Braun J; Rau R
Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
[TBL] [Abstract][Full Text] [Related]
31. Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.
Sharma P; Scott DG
Drugs; 2015 Nov; 75(17):1953-6. PubMed ID: 26474779
[TBL] [Abstract][Full Text] [Related]
32. In brief: otrexup--a single-use auto-injector formulation of methotrexate.
Med Lett Drugs Ther; 2014 Mar; 56(1439):28. PubMed ID: 24691150
[No Abstract] [Full Text] [Related]
33. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis.
Tuková J; Chládek J; Nemcová D; Chládková J; Dolezalová P
Clin Exp Rheumatol; 2009; 27(6):1047-53. PubMed ID: 20149329
[TBL] [Abstract][Full Text] [Related]
35. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF;
Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349
[No Abstract] [Full Text] [Related]
36. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review.
Durán J; Bockorny M; Dalal D; LaValley M; Felson DT
Ann Rheum Dis; 2016 Sep; 75(9):1595-8. PubMed ID: 27091836
[TBL] [Abstract][Full Text] [Related]
37. Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report.
Yokoo H; Nakazato Y; Harigaya Y; Sasaki N; Igeta Y; Itoh H
Acta Neuropathol; 2007 Oct; 114(4):425-30. PubMed ID: 17357801
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
McLean-Tooke A; Aldridge C; Waugh S; Spickett GP; Kay L
Rheumatology (Oxford); 2009 Aug; 48(8):867-71. PubMed ID: 19447771
[TBL] [Abstract][Full Text] [Related]
39. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
40. [Methotrexate: advantages of subcutaneous administration].
Krüger K
Z Rheumatol; 2008 Jul; 67(4):332-3. PubMed ID: 18443809
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
